{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 21/80', '2.1.2.2.', 'Safety Pharmacology', 'The safety pharmacology package conducted to investigate the potential effect of GLPG1690', 'on cardiovascular, respiratory, and central nervous systems did not show any biologically', 'relevant effects.', '2.1.3. Nonclinical Pharmacokinetics and Product Metabolism', 'The absolute oral bioavailability was moderate in rodents (25% to 36%), low in', 'monkeys (14%), and high in dogs (102%).', 'GLPG1690 was highly bound to plasma proteins: 99.1% in human and 97.9-99.6% in rat, dog,', 'mouse, rabbit, and monkey.', 'Overall, GLPG1690 did not extensively distribute into tissues as shown by the low volume of', 'distribution at steady state (Vss) ranging from 0.35 L/kg in the mouse to 0.55 L/kg in the', 'monkey. In rat, [14C]-GLPG1690 was widely distributed throughout the body. Highest', 'concentrations of radioactivity were observed in contents of the gastrointestinal (GI) tract,', 'glandular tissues, liver, and uveal tract. Some affinity was observed of GLPG1690 and/or', 'metabolites for melanin-containing tissues, like uveal tract and meninges.', 'After oral administration, drug-related material is excreted mainly in feces in rat (about 90% or', 'greater). In bile duct-cannulated rats, about 50% of orally administered radioactivity was', 'recovered in bile.', 'Upon repeated once daily (q.d.) oral dosing of GLPG1690, no significant accumulation was', 'observed in plasma, except in male rats (20 mg/kg/day) and dogs (50/65 mg/kg/day at', 'Week 39). Gender differences in PK profiles were observed in rats but not in dogs.', 'The total plasma clearance of GLPG1690 was low in mice, rats, monkeys, and dogs, ranging', 'between 3% and 23% of the hepatic blood flow. Therefore, GLPG1690 is expected to undergo', 'a low first-pass effect after oral dosing.', 'The primary cytochrome P450 (CYP) enzyme involved in GLPG1690 metabolism was', 'CYP3A4. In vitro metabolism studies in hepatocytes revealed 26 potential metabolites.', 'Metabolites formed in human hepatocytes were all present to a similar or higher extent in rat', 'and/or dog hepatocytes, the animal species selected for toxicity studies.', 'An in vitro study with GLPG1690 in human hepatocytes showed no clinically relevant', 'induction of human CYP2B6 and CYP2C enzymes. Weak induction of CYP1A2 and CYP3A4,', 'cannot be excluded at a GLPG1690 dose of 600 mg in human, with a maximal decrease of', 'around 30% in the exposure of a sensitive probe substrate for both CYP enzymes.', 'An in vitro study with GLPG1690 in human liver microsomes indicated no clinically relevant', 'inhibition of the majority of CYP enzymes. Weak competitive reversible inhibition of CYP2C8', 'and CYP3A4/5 cannot be excluded at a GLPG1690 dose of 600 mg in human, with a maximal', 'increase of approximately 1.7- and 1.5-fold, respectively in the exposure of a sensitive probe', 'substrate.', 'GLPG1690 demonstrated a strong time-dependent, irreversible inhibition potential against', 'CYP2C8-mediated metabolism. This could likely lead to a pronounced interaction with a', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 22/80', 'sensitive CYP2C8 probe substrate (increased exposure) if co-administered with a GLPG1690', 'dose of 600 mg in human.', 'No interaction of GLPG1690 is expected with renal uptake transporters, organic cation', 'transporter (OCT)2, organic anion transporter (OAT)1 and OAT3 and hepatic efflux', 'transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). For the hepatic', 'uptake transporters OATP1B1, OATP1B3, and OCT1, and the multi drug and toxin extrusion', '(MATE) efflux transporters MATE1 (hepatic/renal) and MATE2K (renal), a clinical interaction', 'with GLPG1690 cannot be ruled out, however substantial interactions are not anticipated. For', 'the intestinal efflux P-gp and BCRP transporters and the hepatic efflux bile salt export pump', 'transporters an interaction cannot be ruled out.', '2.1.4. Toxicology', '2.1.4.1.', 'General Toxicology', 'A comprehensive toxicology program has been conducted with GLPG1690. This program', 'includes Good Laboratory Practice (GLP) oral repeat-dose toxicity studies of up to 26 weeks in', 'rats and 39 weeks in dogs, embryo fetal development studies in rats and rabbits, fertility studies', 'in male and female rats, non-TgrasH2 mice preliminary studies, preliminary carcinogenicity', 'studies, and i vivo and in vitro genotoxicity studies. Additional toxicology studies conducted', 'include phototoxicity studies and dose range-finding studies in rats and dogs.', 'In', 'rats, no GLPG1690-related mortality was observed. The dose-limiting adverse effects', 'consisted of reduced food consumption and markedly decreased body weight (BW) gain at', '1,000 mg/kg/day in the 4-week toxicity study, histopathological changes in the testes with', 'reduced sperm parameters at >130 mg/kg/day in the 13- and 26-week GLP studies, and the', 'presence of vacuolated alveolar macrophages, with alveolar amorphous material and', 'perivascular inflammatory cell infiltration in the lungs of females in the 26-week GLP study.', 'The no observed adverse effects level (NOAEL) values in rats were set at 40 and 130 mg/kg/day', 'in males and females, respectively, in the 26-week GLP study.', 'In repeat oral dose toxicity studies in dogs, the dose-limiting effects corresponded to decreased', 'white blood cell count and food consumption, emesis and BW loss, associated with poor clinical', 'conditions at doses >100 mg/kg/day in the 13- and 39-week GLP studies, respectively. QT', 'prolongation (in 4-, 13-, and 39-week studies), which was considered non-adverse, were also', 'observed in repeat oral dose toxicity studies in dogs. Additional adverse findings in dogs', 'consisted of adverse altered sperm parameters and inflammatory cell infiltrates in the liver and', 'minimal bile duct hyperplasia at 150/100 mg/kg/day (in the 13-week GLP toxicity study) and', 'QT prolongation (in 4-, 13- and 39-week studies). The NOAEL value in dogs was set at', '50/65 mg/kg/day in the 39-week GLP study.', 'Male and female fertility studies in rats showed that there were no effects of GLPG1690 on', 'mating performance, fertility, or reproduction in either male or female rats at the different dose', 'levels tested. As the effects on sperm and testis proved reversible and had no functional impact', 'on animal fertility parameters, the risk of an impact on male fertility in adult subjects is', 'considered low. In males, the no observed effect level (NOEL) for mating performance and', 'fertility was set at 400 mg/kg/day and the NOAEL for sperm changes was determined at', '40 mg/kg/day; the latter is in line with previous studies (i.e.1 13 week rat study). In females, the', 'NOEL for mating performance and fertility was considered to be 120 mg/kg/day.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}